After being fired, I became the light of medicine

Chapter 73 Beifeng Pharmaceutical’s counterattack!
Three-drug.

Almost any drug will inevitably have cytotoxicity and will have a certain impact on liver and kidney function, the only difference is whether the toxicity is greater or lesser.

This is why most drug instructions state: This drug should be used with caution in patients with impaired liver and kidney function.

Other patients are fine, but hepatitis B patients already have damaged livers and unstable liver function. Now you tell the subjects that our new drug is cytotoxic and hepatotoxic and may cause liver damage.

Who dares to try the medicine?

Therefore, three days after the Phase II clinical trial of "Ekofovir" was launched, Tsingshan Pharmaceutical did not receive a single application from a hepatitis B patient.

The news soon reached Zhang Yang's ears, but Zhang Yang was not too worried.

With his assistance in the improvement, although the "Afovir" currently used in the second phase of clinical trials is still a semi-finished product, its side effects such as cytotoxicity and hepatotoxicity are no different from those of the complete product.

the most important is,

After stimulating the cytotoxicity of "phenylalanine", the current "Afovir" has achieved a 25% cure rate, especially for patients with a small amount of hepatitis B virus in their bodies, the cure rate can even reach 65%!

He believes that as long as the first batch of patients undergo the Phase II clinical trial, once the two-month trial results are completed, there will definitely be more hepatitis B patients participating in the trial with a 25% cure rate!
By then, one or two more drug improvements will increase the cure rate to 75%, which will be enough to successfully enter the third phase of clinical trials and be marketed.

The entire development process of "Ekofovir" also looks more real.

As for how the first batch of patients for Phase II clinical trials will come?
After thinking for a while, Zhang Yang decided to use money to attack the problem, namely subsidies.

"All subjects who participate in the Phase II clinical trial of 'Ekofovir' will receive a subsidy of 20,000 yuan each."

really,

The simplest method is often the most effective. As soon as the news came out, patients immediately came to inquire. Although there are still few, it is much better than in the previous few days.

While Zhang Yang was trying to find a way to advance the Phase II clinical trial, the pharmaceutical companies participating in the "Starlight Project" finally noticed that Tsingshan Pharmaceutical had passed the Phase II clinical trial.

Jiangsu Province, Hengrui Medicine General Manager's Office.

Although Hengrui has many businesses, General Manager Su Lin still asks about the progress of his own "Starlight Project" every month.

"Wenping, how is the progress of our 'HR-006' project to cure hepatitis B?"

Su Wenping is still tall and thin. As Su Lin's absolute confidant, he is currently in charge of the "Starlight Project".

"Boss Su, the HR-006 project is progressing well."

"In recent months, we have increased our R&D investment and transferred several experienced R&D personnel from other projects. In the latest trial, the effective rate of preventing hepatitis B synthesis of 'HR-006' has increased to 38.6%, which is a significant improvement compared to the 29.4% in the first phase of clinical trials."

"Once we can raise the effective prevention rate to more than 50%, our hope of curing hepatitis B will increase greatly!"

Su Lin nodded with satisfaction.

As a person with a background in technical research and development, he is well aware of the difficulty of developing a new drug. It is very rare to increase the effective blocking rate by ten percentage points in just a few months.

He couldn't help but feel much more relaxed.

"What about other pharmaceutical companies? In particular, is there any new progress at Gilead?"

Su Wenping shook his head slightly.

"No."

"Gilead's data in the last two months have been mediocre, and they seem to have hit a bottleneck; and other domestic pharmaceutical companies participating in the 'Starlight Project' have not announced any major progress."

Su Lin was not surprised. After all, drug development usually takes years, so it was normal to see no results in a few months.

Just as Su Lin was about to end his questioning, Su Wenping continued, "However, a week ago, Qingshan Pharmaceutical's drug code-named 'QS-001' successfully passed the Phase I clinical trial and has now entered the Phase II clinical trial."

"Moreover, more information about their drug 'QS-001' has been revealed. This is a drug with strong cytotoxicity. Even the Ethics Review Committee has personally intervened and required them to make clear cytotoxicity labels when promoting clinical trials..."

Tsingshan Pharmaceutical?

Cytotoxicity?
Su Lin was slightly stunned.

In fact, when Tsingshan Pharmaceutical applied to join the "Starlight Project" a few months ago, he was indeed a little worried.

But as Qingshan Pharmaceutical's project failed to even pass the Phase I clinical trial in the past few months, he gradually stopped paying much attention to it.

Hearing the news from Qingshan Pharmaceutical, he quickly took the Phase I trial data handed over by Su Wenping and looked through it, then shook his head slightly after a while.

"Cytotoxicity...are you trying to kill the hepatitis B virus through cytotoxicity?"

“It’s a very novel idea, but you see they revised it four times before passing the first phase of clinical trials. It can be seen that they are probably just trying and probably don’t have a clear idea!”

"How about this, they have just entered the second phase, you can follow up and see if there are any new developments!"

Su Wenping didn't comment and just hummed.

To be honest, he didn't understand Qingshan Pharmaceutical's thinking.

But when he thought of Zhang Yang, he suddenly felt a little uneasy.

Based on his understanding of Tsingshan Pharmaceutical, Zhang Yang does not like to shoot at random. Although the idea of ​​cytotoxicity is very novel, could it be another way of solving the problem for Tsingshan Pharmaceutical?

He's not sure!

"We can't just listen to President Su. We still have to find a way to get more information about Qingshan Pharmaceutical's new drug."

Su Wenping made a decision secretly in his heart.

Hengrui Medicine has not paid much attention to Tsingshan Pharmaceutical, let alone other domestic pharmaceutical companies that participated in the "Starlight Project". Some pharmaceutical companies even noticed the news only after Tsingshan Pharmaceutical entered the second week of Phase II clinical trials.

Of course, there is one company that is an exception.

General Manager’s Office of Beifeng Pharmaceutical.

"Boss, the 'QS-001' project that Zhang Yang and his team are working on has passed the Phase I clinical trial and has now received approval for the Phase II clinical trial!"

"But just as we imagined before, their new drug is indeed highly cytotoxic. Even the Ethics Review Committee personally required that it must be labeled with 'cytotoxicity'!"

"From what I've heard, it's very difficult for them to recruit patients right now. Do you think we should create more trouble for them?"

Ding Jian sat on the leather sofa, a gloomy look in his eyes.

He has not been having a good time recently. The emergence of "Qingshan Afa" has completely reduced the "Eltrombopag" generic drug he invested in to a second-line drug. It can be said that this investment has already caused an irreparable loss!

However, he was not discouraged. Currently, Beifeng Pharmaceutical still has several star products on sale, such as the generic drug "Tenofovir Alafenamide" for the treatment of hepatitis B, and "Cyclosporin" for the treatment of anti-rejection!
These two drugs alone are enough to support Beifeng Pharmaceutical's profit source!
Recently, after hearing that Qingshan Pharmaceutical had joined the "Starlight Project", he paid attention to this matter as soon as possible.

He was not worried that Qingshan Pharmaceutical could develop a drug to cure hepatitis B. What he was thinking about was how to create some trouble for Qingshan Pharmaceutical!

"Idiot, what's the point of causing trouble for them now?"

"Didn't you say last time that Qingshan Pharmaceutical accidentally caused acute liver damage to several patients during the Phase I clinical trial? Go and prepare the information. It will be of great use to me!"

……

PS: Thank you Fengyan Dianyu for the reward of 500 coins!
(End of this chapter)